YAP1 and breast cancer: In another study, combinations of Dasatinib and statins (which induce YAP/TAZ phosphorylation) and pazopanib (which induces proteasomal degradation of YAP/TAZ), with other anti-cancer drugs, like doxorubicin and paclitaxel, inhibited YAP/TAZ-dependent breast cancer cell proliferation.